Gammagard Liquid Approval History

• FDA approved: Yes (First approved May 2nd, 2005)
• Brand name: Gammagard Liquid
• Generic name: immune globulin infusion (human)
• Dosage form: Solution
• Company: Baxter Healthcare Corporation
• Treatment for: Primary Immunodeficiency Syndrome

Gammagard (immune globulin infusion (human)) is an immune globulin infusion (human) indicated as replacement therapy for primary humoral immunodeficiency (PI) in adult and pediatric patients two years of age or older.

Development History and FDA Approval Process for Gammagard Liquid

Date	Article
Jun 26, 2012	Baxter Announces FDA Approval for Gammagard Liquid as a Treatment for Multifocal Motor Neuropathy
Jul 25, 2011	Baxter Announces FDA Approval of Subcutaneous Route of Administration for Gammagard Liquid for Patients with Primary Immunodeficiency
May  2, 2005	Gammagard Liquid Baxter Healthcare Corporation - Treatment for Primary Immunodeficiency Disorders

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.